Related Experiment Videos
Fluoxetine and neuroleptic malignant syndrome
1Department of Psychiatry, Toronto General Hospital, University of Toronto, Canada.
Biological Psychiatry
|September 15, 1990
Summary
Neuroleptic malignant syndrome (NMS) can occur with fluoxetine, even without antipsychotics. Serotonin (5-HT) may play a role alongside dopamine blockade in NMS development.
Area of Science:
- Neuroscience
- Psychopharmacology
- Clinical Medicine
Background:
- Neuroleptic malignant syndrome (NMS) is a rare but life-threatening condition.
- NMS is typically associated with antipsychotic medications due to dopamine blockade.
- Previous NMS cases involved complex medication regimens.
Observation:
- A patient developed NMS while initiating fluoxetine monotherapy.
- The patient had a history of treatment with multiple antipsychotic and antidepressant combinations.
- No concurrent antipsychotic use was noted during the NMS event.
Findings:
- This case suggests fluoxetine monotherapy can precipitate NMS.
- A hypothesis proposes serotonin (5-HT) facilitates NMS in conjunction with central dopaminergic blockade.
- This challenges the traditional view of NMS solely linked to antipsychotics.
Implications:
- Clinicians should consider NMS risk with selective serotonin reuptake inhibitors (SSRIs) like fluoxetine.
- Further research into the role of serotonin in NMS pathogenesis is warranted.
- This finding may impact treatment guidelines for patients at risk of NMS.